Economic information and modeling reportBudget impact model
Model outcomes
3 evidence topics · 6 sources
Budget impact model of cretostimogene grenadenorepvec: model outcomes
No evidence found.
Outcomes recommended for budget impact analysis
“The outcomes of the BIA should be presented in the format of interest to health care decision makers.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In a computer program, options should be provided for different categories of costs to be included or excluded from the analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“If a health condition model is needed for the BIA, it should reflect health outcomes and their related costs in the total affected population for each year after the new intervention is introduced into clinical practice.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Outcomes reported by published economic analyses in the indication
“The primary outcome was 5-year cost-effectiveness, measured by incremental cost-effectiveness ratio (ICER, calculated as incremental cost divided by incremental effectiveness) and net monetary benefit (NMB, calculated as willingness to pay [WTP] X effectiveness - cost).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For each population, we estimated time in progression-free state, total costs, total quality-adjusted life-years (QALYs), total equal value life-years gained (evLYGs), and total life-years (LYs) for each treatment over a lifetime time horizon.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote